chromosome 19 open reading frame 73Genealiases: []
Q-omics provides the consensus-scored C19orf73 profile across patient tissues and cancer cell-line models. C19orf73 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C19orf73 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, C19orf73 RNA expression shows 16,567 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where C19orf73 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C19orf73 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C19orf73 survival associations across molecular data types. C19orf73 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C19orf73 RNA expression–survival associations across cancer types. High C19orf73 expression shows unfavorable associations in KIRC, MESO, ACC and UCS, but favorable associations in HNSC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C19orf73 RNA expression.
This table summarizes C19orf73 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C19orf73. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C19orf73 shows lower tumor expression in KIRC and higher tumor expression in BLCA, COAD, LIHC, LUSC and UCEC. The KIRC box plot shows higher C19orf73 RNA expression in normal versus tumor tissue (log2 FC = −0.603, t-test p < 0.001).
This table shows molecular features associated with C19orf73 in patient tissues and cancer cell lines. In patient samples, C19orf73 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C19orf73 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
